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ABSTRACT 
 
 
Tahmaseb, Kambiz Ph.D., Biomedical Sciences Ph.D. Program, Wright 
State University, 2007.  Biochemical Characterization of hTRF1 and 
hTEP1, Two Proteins Involved in Telomere Maintenance 
 
Telomeres are the structures that protect the ends of linear chromosomes 
from fusion and degradation.  The telomere consists of tandem repeated DNA 
sequences that can range from hundreds of bases to kilo-bases depending on 
the organism.  As the cells of an organism replicate their DNA, these repeats are 
lost due to the end replication problem, where the ends of linear DNA cannot be 
fully replicated.  As the telomeres are shortened through each round of 
replication, they eventually reach a critical point.  Once the telomeres are too 
short and the cell risks losing coding sequences, a signaling pathway is initiated 
that causes the cell to senesce.  However, cells that require continuous 
replication (i.e., stem cells, germ cells, and cancer cells) require constant 
maintenance of their telomeres in order to not enter senescence.  The majority of 
these cells use the multimeric protein telomerase and a host of other proteins to 
maintain the lengths of their chromosomes.  Eukaryotic telomerase is a nucleo-
protein complex consisting of the telomerase RNA (TR), telomere end reverse 
transcriptase (TERT), and telomerase associated protein 1 (TEP1).  
Furthermore, telomeric length is regulated by a host of telomeric binding 
proteins. 
This thesis focuses on two proteins important for human telomeric  
maintenance.  The first is human TEP1 (hTEP1) which is a subunit of 
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telomerase.  This large protein contains the RNA binding domain that binds hTR.  
Though the RNA binding subunit of hTEP1 has been partially purified before, 
full-length hTEP1 has been refractory to biochemical analysis due to the inability 
to express and purify this large protein.  Here we reveal the very first purification 
of full-length hTEP1.  Furthermore, where the RNA binding domain of hTEP1 
alone does not show specific interaction with hTR, we show that full-length 
hTEP1 binds hTR specifically.   
The second protein of interest in this thesis is the human telomeric repeat 
binding factor 1 (hTRF1).  This protein is one of the telomeric binding proteins 
that plays a critical role in telomere structure and stability.  hTRF1 is also 
important as a regulator of telomeric length.  hTRF1 has been shown to bind 
telomeric DNA specifically and my data reveals details of this surprisingly 
complex interaction using a sensitive intrinsic fluorescence kinetic technique.  
Our results demonstrate that hTRF1 binds to both telomeric and non-telomeric 
DNA.  However, hTRF1 exhibits different characteristics as it binds telomeric 
DNA and is able to distinguish between telomeric and non-telomeric tracts of 
DNA. 
This new information on these two key players in the maintenance of 
telomeres will help us further understand how these complex DNA ends are 
preserved in the cell.  Through this knowledge, we can devise better tests in 
understanding how immortal cell lines, such as cancer cells, function and 
proliferate, making it possible to identify novel therapeutic targets to inhibit this 
process. 
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I. BACKGROUND AND SIGNIFICANCE 
History: 
 Organisms containing linear chromosomes face numerous problems with 
maintaining their DNA length.  Unprotected linear DNA may suffer fusion and 
degradation (reviewed in Blackburn & Szostak, 1984).  The specific sequence of 
DNA, which protects chromosomal termini, is referred to as the telomere (telos, 
end; meros, part).  Though the study of telomeres has been quite recent 
compared to other aspects of eukaryotic chromosomes, the study of 
chromosomal ends has been conducted for most of the last century.  The term 
“telomere” was first coined by H. J. Muller (Muller, 1938).  Muller studied 
rearrangements and breakage in the chromosomes of the insect Drosophila 
melanogaster.  He observed that there is a “terminal gene” which “[has] a special 
function, that of sealing the end of the chromosome…and that for some reason a 
chromosome cannot persist indefinitely without having its ends thus sealed” 
(Muller, 1938).   Further observations of the special features of the chromosomal 
ends came from the work of Barbara McClintock.  Along with Muller, McClintock 
also observed that in maize plants, broken chromosomal termini have a 
tendency to fuse, which led to the formation of bridged chromosomes.  These 
fused chromosomes would break during mitosis and result in different genotypes 
which in turn gave the phenotype of variegated kernels.  She also observed that 
the “breakage-fusion-bridge cycle” ceased if the chromosome ends “healed”, 
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which was a process not understood at the time (McClintock, 1939; McClintock, 
1941; McClintock, 1942).  
After the discovery of DNA’s structure (Watson and Crick, 1953), the 
Russian scientist A.M. Olovnikov published the end replication problem theory 
(Olovnikov, 1971).  Olovnikov realized that the ends of linear DNA cannot be 
blunt after replication.  He theorized that there may be two overhangs due to 
incomplete replication by a DNA polymerase.  In his theory, the polymerase 
would sit on the 3’ end of the template strand, and the area at which it sits would 
not be synthesized, thus leading to a 3’ end overhang.  Furthermore, the 
polymerase would travel 5’ to 3’, but would not be able to synthesize the last 
several bases because it would fall off, thus leading to a 5’ overhang.  In both 
cases, the overhang is in the template strand.  Though it was proven that the end 
replication problem does exist, his theory as to how the overhangs formed were 
later shown to be incorrect.  However, Olovnikov theorized that the telomere 
(whose function was unknown at the time) might serve as a buffer for the 
sequences lost due to the end replication problem (Olovnikov, 1971) and this is 
now known to be accurate.  One aspect of the end replication problem which 
Olovnikov did not consider was the RNA primer used in the synthesis of the 
lagging strand.  It was J.D. Watson and his studies of T7 DNA who described the 
existence of 3’ overhangs after replication (Watson, 1972).  In this study Watson 
theorized that Okazaki fragments may cause incomplete replication of the 
lagging strand, though at the time it was not clear how Okazaki fragments were 
formed and processed. 
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The telomere field was stimulated by studies on the protists, specifically 
trypanosomes and Tetrahymena.  Some of these protists are the cause of 
parasitic diseases such as malaria, and are of medical interest.  They were also 
easy to cultivate and study, especially for the study of telomeres, because they 
have a tendency to carry fragmented chromosomes which in turn translates into 
many termini.  In Tetrahymena it was discovered that these termini contain a 
tandem repeat sequence of dTTGGGG (Blackburn and Gall, 1978).  In 
trypanosomes some of the active surface antigen genes lie at the telomeric ends 
so attention was focused on to the telomeres.  It was demonstrated that the 
telomeres of these unicellular organisms go through length maintenance (Pays 
et al., 1983).  This length maintenance was later explained by the discovery of 
the enzyme telomerase (Greider and Blackburn, 1985).  The telomere field was 
then underway, and the sequence of the human telomere (Moyzis et al., 1988) 
and telomerase activity were demonstrated in human cells shortly after (Morin, 
1989). 
Telomere Structure: 
As previously mentioned, the end replication problem causes telomeres to 
have overhangs at the 3’ end (Figure 1).  Through multiple cell divisions, the 
short 5’ ends lead to shorter DNA molecules.  If the DNA ends are not protected 
by telomeres, the organism will lose genes close to the termini (for reviews 
Blackburn & Szostak, 1984; Dandjinou et al., 1999; Holt & Shay, 1999).  The 
human telomere consists of the 5’d (TTAGGG) tandem repeats and can range 
from 2-15kbp (Moyzis et al., 1988).  Telomeres shorten through cell divisions 
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both in cell culture and in whole tissues (Harley et al., 1990; Hastie et al., 1990; 
Counter et al., 1992), and the rate is proportional to the length of the 3’ overhang 
(Huffman et al., 2000).  Once the protective telomere has become too short, the 
cell will stop dividing and irreversibly arrest in the G1 phase of the cell cycle, also 
known as senescence.  
The end replication problem, which leads to senescence, is thought to be 
a result of discontinuous replication of the lagging DNA strand.  As the RNA 
primers of the Okazaki fragments are removed, the final primer at the 5’ end is 
not replaced by DNA, making this strand shorter.  However, in vivo observations 
have revealed that the 3’ overhangs of chromosomes are 45 to 210 bp long 
(Makarov et al., 1997; McElligott & Wellinger, 1997; Wright et al., 1997) (instead 
of the shorter length of an RNA primer), and on average about 50 bp of 
telomeres are lost after each population doubling (Harley et al. 1990). Recent in 
vitro studies have demonstrated that the lagging strand is not primed and 
extended near the last 500 bp of the 3’ complementary strand (Ohki et al., 2001).  
This in vitro observation supports the in vivo finding and suggests that the 
telomere shortening is the result of both the removal of the RNA primer from the 
5’ end and the inability of DNA primase to prime and synthesize at the ends of 
chromosomes.  Furthermore, it is expected that replication of the original 5’ 
strand will lead to a blunt ended DNA molecule due to continuous synthesis of 
the new 3’ strand.  However, it has been demonstrated that both yeast and 
mammalian cells maintain 3’ overhangs on all chromosomes (Dionne & 
Wellinger 1996; Wellinger et al., 1996; Makarov et al., 1997; Hemann & Greider, 
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1999).  Therefore, blunt chromosome ends are processed to obtain 3’ 
overhangs, suggesting that this structure is vital for cell function.  Evidence also 
suggests that the overhangs are a result of 5’ end degradation instead of 3’ end 
elongation (Dionne & Wellinger 1996; Wellinger et al., 1996; McElligott & 
Wellinger, 1997). 
Once these 3’ overhangs are generated, one must consider how these 
ends are maintained.  There are two theories as to how the overhangs are 
managed in the nucleus.  The first theory is that they adopt a G-quartet structure.  
It has been demonstrated that DNA sequences with high guanosine content 
have a tendency to form base pairs between the guanosines (Henderson et al., 
1987; Williamson, 1989).  This G-G base pairing has the potential to form higher 
order structures such as hairpins, double hairpins, pseudoknots (Henderson et 
al., 1987), and G-quartets (Williamson, 1989). As the name implies, a G-quartet 
is a structure where four guanosines form hydrogen bonds in a square planar 
fashion.  However, the G-quartet model has only been shown in vitro using 
protist telomeric DNA which is more G-rich than the mammalian counterpart.  
The mammalian telomeric repeat only forms G-quartets under non-physiological 
conditions such as high temperatures and/or low pH (Phan and Mergny, 2002). 
The other theory for the maintenance of the telomeric overhangs is the t-
loop model.  The t-loop is formed when double-stranded telomeric DNA loops 
back upon itself, and the single-stranded 3’ overhang becomes embedded within 
the double stranded telomeric tract (Griffith et al., 1999).  The portion where the 
single stranded DNA is embedded in the double stranded region is known as the 
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D-loop.  Recent in vitro experiments using electron microscopy have further 
supported the t-loop theory (Muñoz-Jordán et al., 2001; Stansel et al., 2001).  
The t-loop is facilitated and kept by the telomeric binding factor TRF2 (see next 
section for further details).  Currently, the t-loop theory is the accepted model for 
mammalian telomere structure to maintain the end in a nonrecombinogenic state 
and protected from detection by DNA damage recognition proteins.  This is 
demonstrated by the fact that cells, which have sufficient telomeres, may still 
senesce or apoptose once telomere end maintenance by the telomeric binding 
factors has been prohibited and hence the DNA end left exposed.  Van Steensel 
et al. (1998) and Karlseder et al. (1999) demonstrated that the expression of the 
dominant negative mutant of TRF2 in immortalized cell lines induced 
senescence and apoptosis due to destabilization of the telomere ends from lack 
of binding by TRF2. 
Telomeric Proteins and RNA:  
In order to continue cell division, some cells activate the enzyme telomere 
terminal transferase (telomerase) (for review Liu, 1999) which extends the 
telomeric 3’ end de novo.  Telomerase was first isolated from the protist 
Tetrahymena (Greider & Blackburn, 1985) and later its activity was demonstrated 
in humans (Morin, 1989). Telomerase is specific for telomeric repeats.  The 
mammalian telomerase recognizes and extends the single stranded 
d(TTAGGG)n 3’ end of chromosomes.  Due to the guanine content of the 
telomeric 5’-3’ strand, it is referred to as the G-strand and inversely the 3’-5’ 
strand is known as the C-strand.  Telomerase is a cellular reverse transcriptase 
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which uses an intrinsic RNA template termed hTR (human telomerase RNA) to 
extend telomeric DNA.  The two known protein components are the catalytic 
subunit (TERT) and another associated subunit of unclear function (TEP1) which 
we studied further and describe the findings in this thesis.   
 The telomerase catalytic subunit is known as the telomere end reverse 
transcriptase (TERT).  Most human cells do not express the TERT subunit, 
resulting in no telomerase activity (Meyerson et al., 1997; Nakamura et al., 
1997).  hTERT was cloned by two labs simultaneously and was found to be 
composed of over 1100 amino acids with an estimated size of 127 kDa 
(Meyerson et al., 1997; Nakamura et al., 1997).  The introduction of hTERT into 
telomerase negative cells leads to longer telomeres and increased replicative 
potential (Bodnar et al., 1998; Counter et al., 1998a).  Conversely, the induction 
of a dominant-negative mutant of hTERT in telomerase positive cancer and 
immortalized cell lines leads to a decrease in telomere length and increased cell 
death (Zhang et al., 1999).   
 The structure of telomerase and regulation of telomerase activity remains 
to be fully elucidated.  It has also been demonstrated that telomerase is a 
phosphoprotein, and PKCα is involved in the phosphorylation of telomerase (Li 
et al., 1998).  It is known that inhibition of protein kinase C (PKC) (Ku et al., 
1997) as well as in vitro addition of protein phosphatase 2A (PP2A) (Li et al., 
1997) inhibit telomerase activity.    Furthermore, any deletions in both the C and 
N-termini (outside of the catalytic domain) of hTERT completely diminish any 
enzymatic activity (Bachand and Autexier, 2001).  It is not known whether these 
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termini are required for phosphorylation of hTERT, but they are not required for 
binding the telomeric RNA template molecule (hTR) (Bachand and Autexier, 
2001).  However, it is known that the deletion of amino acids 301-538 in the N-
terminus and amino acids 914-928 in the C-terminus do keep hTERT from 
oligomerizing and inhibit telomerase activity.  These mutants also have the ability 
to serve as dominant negatives, indicating that hTERT is most likely a dimer 
(Arai et al., 2002).  It is also known that the C-terminus of hTERT is essential for 
telomerase maintenance.  Though catalytically active, a tag on the hTERT C-
terminus can keep telomerase from maintaining the telomeres of an 
immortalized cell line (Counter et al., 1998b; Ouellette et al., 1999). 
The RNA molecule that hTERT uses as a template to synthesize 
telomeric repeats de novo is called hTR (Feng et al., 1995).  hTR and hTERT 
are sufficient for telomerase activity in vitro (Masutomi et al., 2000).  Telomerase 
deficient mice created by deletion of mTR gene are shown to suffer from genetic 
instability and shorter life span (Blasco et al., 1997; Rudolph et al., 1999).  
Mutations in hTR lead to defects in cells which require continuous division (i.e. 
skin, gut, and bone-marrow) and leads to dyskeratosis congenita in humans 
(Vulliamy et al., 2001).  Bone-marrow failure and abnormal skin pigmentation 
characterize this disorder.  This evidence further supports the theory that 
continuously dividing cells require the protection of telomeres and telomerase to 
continue normal function. 
hTR is a RNA molecule of roughly 450 bases in length and with a complex 
secondary structure (Chen et al., 2000) (Figure 2).  In addition to containing the 
 9 
telomeric template, the hTR molecule has conserved CR4-CR5,  H/ACA box, 
CR7, and the pseudoknot domains (Chen et al., 2000).  Different deletion 
mutations have demonstrated that the first 159 nucleotides of hTR are sufficient 
for binding hTERT but not sufficient to produce telomerase activity, which 
requires the sequences between nucleotides 276-424 as well (Bachand and 
Autexier, 2001).  This study and others (Chen and Greider, 2003) demonstrate 
that the presence of the template sequence is not enough for telomerase activity 
and that the hTR secondary structure plays a major role as well.   
The final known telomerase subunit and one of particular interest in this 
research is telomerase associated protein 1.  Human TEP1 (hTEP1) was cloned 
and characterized by the Harrington lab, and was found to be 2629 amino acids 
long resulting in a protein of 240 kDa (Harrington et al., 1997).  hTEP1 interacts 
specifically with hTR in vivo like hTERT, and this activity is conserved through 
multiple species (Harrington et al., 1997).  In fact, hTEP1 shares one third of its 
length with the Tetrahymena p80, which is a telomeric subunit of Tetrahymena. It 
was this homology with p80 that led to the discovery of TEP1 in the mammalian 
system.   
In addition to the RNA binding domain that hTEP1 shares with p80, 
mammalian TEP1 also contains a series of WD40 repeats, and a nucleotide 
binding domain (Figure 3).  WD40 repeats have been shown in other proteins to 
be important for protein-protein interactions (reviewed in Neer et al., 1994).   
TEP1 knockout mice have been shown to have normal telomere ends and 
telomerase function (Liu et al., 2000), thus the authors generalize that TEP1 is 
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not important in telomere function and maintenance in mammals.  However, 
mice have different telomere length maintenance and telomerase activity than 
that found in humans.  Furthermore, it is highly unlikely that a protein would be 
conserved across species and kingdoms, but not serve a crucial role in cellular 
function.  Part of this function may lie in the interaction of hTEP1 with a large 
cytoplasmic ribonucleoprotein known as the vault particle (Kickhoefer et al., 
1999), although the reason for this interaction remains to be elucidated as the 
role of vault particles remains an unknown.   
Though hTEP1 has been cloned, it has not been purified, which may be 
because of hTEP1’s large size and instability in solution.  Other than the 
research done in this dissertation, there has been one other published account 
of hTEP1 purification.  In this purification scheme only the p80 homology domain 
of hTEP1 was partially purified (Poderycki et al., 2005).  Though this domain did 
successfully bind hTR and vault RNA’s in vivo, little specificity was detected 
during binding experiments in vitro.  As it will be demonstrated in this 
dissertation, this lack of specificity in vitro is due to the absence of the other two 
thirds of the protein.  I will show later that the full length hTEP1 does show 
specificity in binding hTR in vitro. 
In addition to telomerase, there are other proteins involved in the 
maintenance of telomeres.  Telomeric elongation and stability are maintained by 
the binding of telomeric repeat binding factors (for review Greider, 1996).  Two 
known telomeric repeat binding factors in the mammalian system are telomeric 
repeat binding factors 1 and 2 (TRF1 and TRF2).  Both of these proteins are 
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specific for double stranded telomeric DNA (Broccoli et al., 1997).  TRF1 was 
first identified and characterized by the de Lange laboratory (Chong et al., 1995) 
and regulates the maintenance of telomeric length (for review Smith and de 
Lange, 1997).  TRF1 has the ability to bind and bend telomeric DNA to an angle 
of approximately 120
o
 which is thought to be important for telomeric maintenance 
(Bianchi et al., 1997).  Binding of TRF1 to telomeric DNA is not cooperative, yet it 
is length dependent, with longer telomeric tracts increasing TRF1 binding in vitro 
using electrophoretic mobility shift assays (EMSA) (Zhong et al., 1992).  This 
evidence supports the hypothesis that the shortening of telomeres results in less 
TRF1 binding.   
The binding of TRF1 to telomeres negatively regulates their extension.  
Inversely, inhibition of TRF1 in telomerase positive cells leads to telomeres of 
increasing length (van Steensel and de Lange, 1997), however the exact 
mechanism of telomeric length regulation by TRF1 is unknown.  In vitro 
experiments demonstrate that TRF1 and TRF2 are not capable of reducing 
telomerase expression levels (Smogorzewska et al., 2000).  It has recently been 
shown that TRF1 directly interacts with POT1 (protector of telomeres 1), which is 
a single strand telomeric binding factor.  The same study has demonstrated that 
TRF1 is responsible for POT1 loading onto single stranded telomeric ends, and 
that removal of TRF1 or the mutation of POT1 correlates with increased 
telomeric length.  This study suggests that POT1 may be one factor involved in 
length regulation by TRF1 (Loayza and de Lange, 2003).  Another pathway by 
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which hTRF1 may control telomere length is through the inhibition of C-strand 
synthesis, which is further described in the next section. 
TRF2 has been demonstrated to be involved with stabilizing telomeric 
structures rather than regulation of telomeric length.  Inhibition of TRF2 leads to 
loss of G-strand overhangs, covalent fusion of telomere termini, chromosomal 
fusion, and apoptosis (van Steensel et al., 1998; Karlseder et al., 1999). 
Stabilization of telomeres by TRF2 is thought to arise from its ability to stabilize 
the t-loop structure of telomeres (Figure 4).   
Both TRF1 and 2 form homodimers and contain a Myb-like helix-turn-helix 
DNA binding domain in their carboxy end which is required for sequence-specific 
binding of telomeres (König et al., 1998).  Studies have demonstrated that TRF1 
and 2 have high specificity for the mammalian telomeric repeat sequences 
(Zhong et al., 1992; Broccoli et al., 1997; Krutilina et al., 2001).  Though TRF1 
and 2 share similarities in motifs and activity, they do not heterodimerize 
because the N-terminus required for dimerization in TRF1 is acidic and the N-
terminus of TRF2 is basic (Broccoli et al., 1997).  This supports the observation 
that these proteins have non-overlapping functions at telomeres.   
As telomeres shorten, fewer telomeric binding factors may bind, which 
may lead to unstable telomeres (Smogorzewska et al., 2000).  This instability 
translates into the exposure of the telomeric ends, which would normally be 
concealed in the t-loop, which in turn can be detected as damaged DNA and 
lead to cellular senescence.  This theory is further supported by the observation 
that unstable telomeres form dicentric chromosomes (Karlseder et al., 1999).  
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This observation demonstrates that the exposed telomeric ends do not separate 
in mitosis due to fusion.  Depletion of TRF2 activity by a dominant-negative 
mutant causes senescence via p53 and p16/RB pathways, which are the same 
pathways that cause senescence in normal cells (Smogorzewska and de Lange, 
2002), providing more evidence that senescence from short telomeres is caused 
by a lack of binding by TRF’s.  
All of the previous biochemical work on TRF1 and 2 have been steady 
state measurements of their activities.  The ability of TRF1 to regulate telomeric 
length makes it an ideal candidate to study biochemically in order to understand 
telomeric function better.  Therefore, in the body of this work we will show pre-
steady state kinetic studies on TRF1 and its interaction with DNA, further 
demonstrating that this interaction is much more complex than previously 
thought. 
Cellular Implications of Telomeres, Coordinated Synthesis, and Significance: 
As mentioned previously, the works of Muller (1938) and McClintock 
(1939; 1941; 1942) have demonstrated the importance of chromosome ends.  
Telomeres are important in the protection of chromosomes from degradation and 
fusion.  Due to the end replication problem, telomeres shorten and upon 
reaching a critical length the host cell stops dividing.  This halting of cellular 
division is known as senescence.  Senescence may be caused by telomeric 
instability induced by the shortening of the telomere (Counter et al., 1992), 
though it may also be caused by oxidative stress and oncogene activation (for 
review Lundberg et al., 2000).  Shortened telomeres are recognized as damaged 
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DNA since the ATM (ataxia telangiectasia mutated) and p53 pathways are 
activated (Vaziri et al., 1997).  Both ATM and p53 are involved in damage 
recognition, induction of senescence, and apoptosis in damaged cells.  
Furthermore, deactivation of the p53/pRb pathways leads to cells which continue 
to divide until crisis is reached (cells in crisis continue cell division through the 
loss of telomeres and coding sequences of the genome) (Vaziri & Benchimol, 
1999).  This supports the hypothesis that shortened telomeres are recognized as 
damaged DNA, because the deactivation of the damage recognition proteins 
leads to cells that do not senesce. 
In order for cells to have unlimited replicative potential without major 
chromosomal malfunction, they need to continuously elongate their telomeres, 
which is where the protein telomerase becomes involved.  As mentioned 
previously, telomerase selectively extends telomeric G-strand de novo.  
Therefore, it is not surprising that most immortalized cell lines and tumor cells 
possess telomerase activity (Counter et al., 1992; Kim et al., 1994). Telomeres 
are very important in the study of many cancer types.  Telomerase activity is 
crucial to the growth of tumor cells, because without it the telomeres would 
diminish and the cells would senesce or reach crisis.  Therefore, it is important to 
understand how telomere length can be regulated. 
However, telomerase is only part of the equation.  Little is known about C-
strand synthesis.  Understanding the complete synthesis of telomeres is the only 
way to fully understand how telomere maintenance is regulated.  There is some 
evidence that C-strand synthesis occurs with the aid of polymerase alpha 
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primase (Pol α).  Studies done in our lab and others have demonstrated that Pol 
α is capable of priming and synthesizing telomeric tracts (Reveal et al., 1997; 
Nozawa et al., 2000).  Since no other priming polymerase has been identified for 
telomere synthesis, it is most likely that Pol α is functioning in C-strand synthesis.  
Our lab has also demonstrated that TRF1 is capable of inhibiting Pol α’s ability to 
function on telomeric tracts (Smucker and Turchi, 2001).  This interaction may 
very well explain why TRF1 is a negative regulator of telomere length, unlike the 
current dogma that assumes TRF1 inhibits G-strand synthesis, which has not 
been recapitulated. 
Due to the complexity of telomeres and telomerase, it is very important to 
biochemically understand the role and function of each component.  In this work, 
I isolated and studied two important components of telomeric maintenance: 
hTRF1 and hTEP1.  Both proteins were purified and studied.  In the case of 
hTEP1, the purification scheme outlined in these pages is the first successful 
purification of the full length protein.  For hTRF1, though it has been previously 
purified successfully, I will discuss the first pre-steady state kinetics performed 
on this protein.  Overall, this work is one more step towards understanding how 
telomeres function, and eventually may lead to a significant leap into our general 
understanding of cancer.
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Figure 1.  Simple schematic of the end replication problem.  The black lines 
represent the original strands and the red lines represent the newly synthesized 
strands, with the blue line representing the RNA primer of the Okazaki fragment.  
On the right side, the short 5’ strand leads to the formation of a short 3’ strand, 
and upon processing the original 5’ end becomes even shorter than before.
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Figure 2.  The predicted secondary structure of hTR adapted from Bachand and 
Autexier, 2001.  The box between bases 46 and 53 is the template region of 
hTR.
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Figure 3.  Schematic of the hTEP1 domains adapted from Harrington et al., 
1997.  a. The N-terminal repeats of hTEP1.  b. The Tetrahymena p80 homology 
domain.  c. The nucleotide binding domain.  d. WD40 repeats.
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Figure 4.  Schematic model of a telomeric t-loop.  The blue proteins represent 
TRF1 and the red represent TRF2.  The loop formed in the immediate vicinity of 
the infiltrating 3’ end is the D-loop and is supported by TRF2.
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II. MATERIALS AND METHODS 
Cloning:   
hTR:  Whole cell RNA was extracted using the TRIzol
®
 reagent 
(Invitrogen, Carlsbad, CA) and the instructions provided with the reagent.  Briefly, 
confluent 293-S cells grown in a monolayer in a 35 mm dish were lysed by 
adding 1 ml of TRIzol
®
 reagent.  The solution was pipetted up and down to 
facilitate lysis.  The solution was allowed to sit at room temperature for 5 
minutes.  200 µl of chloroform was added to the lysis solution and shaken by 
hand to allow mixing.  The solution was then centrifuged at 10,000 X g in a table-
top centrifuge for 10 minutes at 4
o
C.  The upper aqueous phase containing the 
RNA was removed and mixed with 0.5 ml of isopropanol.  This solution was 
incubated in room temperature for 10 minutes and subsequently centrifuged as 
previously stated.  The resulting pellet was washed using 1ml of 70% ethanol 
and re-centrifuged at 6000 X g for 5 minutes at 4
o
C.  The pellet was then air 
dried, and dissolved in DEPC treated water.  Absorption spectrophotometry was 
used to quantify the amount of RNA; agarose gels were used to assess the 
quality. 
   To generate single-stranded cDNA, the cDNA Cycle
®
 Kit (Invitrogen, 
Carlsbad, CA) was employed using the kit guidelines.  Briefly, the whole cell 
RNA was thawed on ice and 5 µg was used in each reaction.  Random primers 
were added to the RNA.  The solution was heated to 65
o
C for 10 minutes to 
remove the RNA secondary structure.  The mixture was cooled to room 
temperature to allow primer binding and final reagents provided by the kit were 
added to the RNA/primer mix.  The reagents included RNase inhibitor, reverse 
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transcription buffer, dNTP’s, sodium pyrophosphate, and AMV reverse 
transcriptase.  Upon mixing the solution, it was incubated at 42
o
C for one hour 
for reverse transcription to occur.  Then the reaction was stopped by incubating 
the solution at 95
o
C for 2 minutes and then placed on ice.  Subsequently the 
solution was chloroform/phenol extracted and ethanol precipitated and 
resuspended in DEPC treated water. 
To amplify the cDNA of hTR, polymerase chain reactions (PCR) were 
performed.  For the PCR experiments, reactions were carried out using the 
FailSafe
TM
 PCR System in 25 µl.  The specifics of this reaction are given under 
the results section. 
The hTR cDNA was cloned into the pCR
®
-Blunt II-TOPO
®
 vector using the 
Zero Blunt
®
 TOPO
®
 PCR cloning kit (Invitrogen, Carlsbad, CA).  This kit allows 
for the cloning of blunt-ended PCR products into the vector without the use of 
restriction enzymes.  Following the directions of the kit, the newly formed 
plasmids were used to transform TOP10 E. coli (provided by the kit).  The 
transformed cells were plated and incubated overnight at 37
o
C.  After the 
incubation, five colonies were picked for further analysis.  These colonies were 
grown in 5 ml of LB broth overnight at 37
o
C in a shaker.  The next day, the cells 
in each tube were sedimented for one minute at 8,000 X g on a table top 
centrifuge and a miniprep was performed using the QIAprep Spin Miniprep Kit 
(Qiagen, Valencia, CA).  The plasmid yield was quantified using absorbance at 
260 nm.  The plasmids were then digested with restriction enzymes to confirm 
that hTR was properly cloned.  One of the plasmids was then chosen to be sent 
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for sequencing by Cleveland Genomics (Cleveland, OH).  Upon confirmation of 
the correct sequence, hTR was excised out of the pCR
®
-Blunt II-TOPO
®
 vector 
using SacI and EcoRI restriction enzymes for insertion into the plasmid pBS+ 
which was also digested with the same restriction enzymes.  The digested 
plasmid and insert were gel-purified using a 1% low melting point agarose gel 
with 1.5 µg/ml crystal violet dye run in 1X TAE buffer (40 mM Tris-acetate, 40 
mM acetic acid, and 40 mM EDTA, pH 8.5).  Crystal violet allows for the 
visualization of the DNA bands directly without the use of UV light which can be 
very damaging to the DNA.  The DNA bands of the right size were cut out of the 
gel and the DNA was extracted using the QIAquick Gel Extraction Kit (Qiagen, 
Valencia, CA).   
hTR was ligated into pBS+ by adding 400 ng of gel purified hTR to 45 ng 
of gel purified pBS+.  The ligation mix also included 1X ligation buffer (50 mM 
Tris-HCl, 10 mM MgCl2, 1 mM ATP, 10 mM DTT, 25 µg/ml BSA, pH 7.5 at room 
temperature), and 400 units of T4 DNA ligase (New England Biolabs, Ipswich, 
MA), all brought up to 20 µl by the addition of sterile water.  Each reaction was 
incubated at 16
o
C overnight.  As a negative control, the double digested vector 
without an insert was ligated, and as a positive control the vector with a single 
cut was ligated.  After the ligation reactions were completed, the reactions were 
stopped by the addition of 20 mM EDTA.  Then TOP10 E. coli were transformed 
using 4 µl of each reaction mix and plated.  The plates were incubated at 37
o
C 
overnight.  The next day, hTR colonies were checked using a quick PCR 
method.  In this method, each bacterial colony was touched with a sterile tip and 
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then touched to the bottom of a PCR tube.  Once 10 colonies were sampled this 
way, the tubes were heated in a microwave oven for 3 minutes to lyse the 
bacteria.  The PCR mix for hTR was added to each tube and the PCR reactions 
were carried out using the procedures noted in the results section.  The PCR 
products were analyzed using an agarose gel to determine which colonies 
contained the hTR insert.  The selected colonies were then grown in LB broth for 
a maxiprep using Qiagen Plasmid Maxi kit (Qiagen, Valencia, CA) to obtain a 
larger quantity of the pBS+-hTR plasmid.  Further restriction digests were 
performed to confirm the formation of pBS+-hTR and that hTR is in the correct 
orientation in relation to the T7 promoter. 
hTEP1:  All cloning specifics for hTEP1 are presented in the results 
section.   
hTRF1:  The hTRF1 cDNA was amplified from the Human Full Length 
cDNA kit (Panomics, Redwood City, CA).  The reaction mixture included 1X 
cDNA buffer, 50 pmol of hTRF1 sense primer 
(5’ACGGCTAGCATCGAGCCATTTAAC 3’) and hTRF1 antisense primer (5’ 
GATCTGCAGAGCTTTTACAAACAC 3’), and 1 µl of human hull length cDNA.  
This mixture was heated in the thermocycler for 2 minutes at 82
o
C and then 2 µl 
of rTth polymerase (Applied Biosystems, Foster City, CA) was added.  Upon the 
addition of rTth, the reaction was heated to 94
o
C for 1 minute followed by 40 
cycles of 94
o
C for 30 seconds, 55
o
C for 1 minute, and 68
o
C for 1 minute and 30 
seconds.  The cycles were followed by a final elongation step at 68
o
C for 10 
minutes.  The reaction tube was stored at 4
o
C for further analysis by agarose gel 
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electrophoresis.  Upon confirmation of a band at 1.6 kbp the PCR product was 
cloned into the pCR
®
-Blunt II-TOPO
®
 vector as described earlier.  The cloned 
hTRF1 was analyzed using restriction digests.  Once it was confirmed that 
hTRF1 was present, it was cloned into the pRSET B vector (Invitrogen, Carlsbad, 
CA).  The pRSET B vector was chosen because it includes the sequences for a 
poly-histidine tag (His-tag) and an XPress tag, 5’ of the targeted cDNA.  pCR
®
-
Blunt II-TOPO
®
-hTRF1 and pRSET B were both treated with BamHI and PstI 
restriction enzymes and gel-purified as described above.  The gel-purified 
products were ligated as previously described, creating His-tagged and XPress-
tagged hTRF1.  His-XPress-hTRF1 was then cloned into pBacPAK 8 for the 
creation of a baculovirus.  For this process, His-Xpress-hTRF1 and pBacPAK 8 
were treated with XbaI and KpnI, and the fragments were purified and ligated as 
stated earlier. 
Cell Culture: 
 All proteins in this work were expressed in the SF9 (Spodoptera 
frugiperda) cell culture system.  Frozen SF9 cells at 3X10
6
 cells/ml were thawed 
and plated on a 100 mm dish in Grace’s insect cell culture media (1liter contains 
45.72 g of powdered media, 350 mg of sodium bicarbonate, 20 ml of 50X 
yeastolate, 3.3 g of lactalbumin, 10 ml of 100X penicillin-streptomycin, and 2 ml 
of 50 mg/ml Gentamicin), supplemented with 20% FBS and grown at 28
o
C.  After 
the first 2-3 days, the cells were fed using Grace’s media with only 10% FBS.  
Upon becoming confluent, the cells were scraped off using a rubber policeman 
and split into two 150 mm plates.  Once the two plates were confluent the cells 
 29 
were scraped again and placed into a 250 ml spinner flask in 100 ml of media.  
Cells were grown until a concentration of 1X10
6
 cells/ml was reached, at which 
time they were split down to 2.5-5X10
5
 cells/ml depending on how quickly more 
cells were needed. 
Baculovirus: 
 Construction:  The BacPAK™ Baculovirus Expression System (Clontech, 
Mountain View, CA), was used to generate the baculoviruses needed for these 
projects.  In brief, 1X10
6
 cells in 1-2 ml of media were plated on a 35 mm dish.  
Once all of the cells had attached (1-2 hours) the media was removed and cells 
were washed with basic media (no FBS).  After the wash, cells were allowed to 
sit in 2 ml of basic media for 30 minutes.  During this incubation, 500 ng of 
pBacPAK 8 with the desired cDNA insert was mixed with 5 µl of Bsu36I digested 
pBacPAK 6 (provided by the kit), and the final volume was adjusted to 96 µl 
using sterile water.  4 µl of Bacfectin (transfection reagent provided by the kit) 
was added to the mix and was allowed to incubate for 15 minutes at room 
temperature.  Upon the completion of all incubation steps, the media was 
removed from the cells and 1.5 ml of fresh basic media was added to the cells.  
The DNA-Bacfectin mix was then dripped into the media of the cells while 
swirling the plate.  The transfection was allowed to continue for 5 hours at room 
temperature, and then 1.5 ml of complete medium was added to the cells and 
the plate was incubated for 72 hours.  After 72 hours the media, which included 
the primary virus, was removed from the cells and sterile filtered to remove any 
cells or debris.   
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Plaque purification:  To generate plaque purified virus, a plaque assay 
was performed on the primary virus.  First, a 1:10 serial dilution was performed 4 
times using insect media, so that at the end there were five tubes; undiluted, 10
-
1
, 10
-2
, 10
-3
, and 10
-4
.  Then, SF9 cells were plated into the 6 wells of a 6- well 
dish (each well is the size of a 35 mm dish) at a concentration of 1X10
6
 cells per 
well.  Once all cells had attached, the media was removed and 125 µl of each 
virus dilution was added to each cell layer, with 125 µl of media added to the last 
well as a negative control.  The lid of the plate was placed back and wrapped 
with Parafilm to avoid evaporation of the small liquid amount inside.  During the 
incubation, sterile 2% low melting point agarose (melted) was mixed with equal 
volume of Grace’s insect cell media to make a 1% agarose solution and stored in 
a 42
o
C water bath to prevent solidification.  After the incubation of the cells, the 
virus was removed and 1.5 ml of the agarose solution was added to the cells and 
allowed to solidify.  1.5 ml of media was added to the top of the agarose plug 
and the plates were allowed to incubate for 5 days.  After the 5 days, the media 
on top of the agarose plug was removed and 1ml of 0.03% neutral red dye 
(diluted in sterile 1X PBS) was added to the top.  The neutral red was allowed to 
soak in for 1-2 hours, removed, and the plates were inverted and incubated in 
the dark overnight.  The next day, plaques where the cells had died would 
appear as clear spots in a background of red.  Five plaques were then chosen to 
be amplified as plaque purified virus.  The plaques were picked using glass 
Pasteur pipettes and resuspended in 1 ml of media.  The virus was allowed to 
diffuse out overnight, after which the tube was spun down at 8,000 X g on a table 
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top centrifuge to remove any floating agarose or debris.  The resulting 
supernatant was termed the plaque purified primary virus.  One 0.5 ml aliquot of 
this virus was placed in a cryogenic tube and stored in 
-
80
o
C, and the rest was 
kept at 4
o
C in the dark. 
Plaque Assay:  The steps for the plaque assay are very similar to those of 
plaque purification with some minor adjustments.  Since higher titers of virus are 
involved for the plaque assay, dilutions were made in the range of 10
-3
 to 10
-8
.  
Also instead of removal, the viral plaques were counted.  In order to determine 
the titer, the following equation was followed: 
Titer (pfu/ml) = (#of plaques X 8)/dilution factor 
In these studies the number of plaques were multiplied by 8 because 125 µl of 
virus was used and we want to know the titer in ml (8 X 125 µl = 1 ml).  The units 
of the titer represent plaque forming units (pfu) per milliliter of virus. 
Amplification:  For the amplification of the plaque purified virus, SF9 cells 
were plated on 35 mm dishes at a concentration of 5X10
5
 cells per dish.  Once 
cells had attached to the plate, 100 µl of plaque purified virus was added to the 
media.  The plates were incubated at 28
o
C for 5 days.  Upon the completion of 
the incubation, the media was removed and sterile filtered.  This aliquot of virus 
was called the secondary virus.  The secondary virus was then titered using the 
plaque assay procedure.  One 1 ml aliquot of this virus was placed in a cryogenic 
tube and stored in 
-
80
o
C, and the rest was kept at 4
o
C in the dark.  The cells 
from this amplification were lysed in SDS sample buffer, heated to 85
o
C, and 
processed for Western blot analysis (described later). 
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For the amplification of secondary virus, 50 ml suspension culture of SF9 
cells was prepared in a 100 ml spinner flask.  The suspension culture was 
seeded at 5X10
5
 cells/ml, and 5X10
4
 pfu/ml of secondary virus was added.  The 
suspension culture was then allowed to spin for 5 days at room temperature.  
Upon the completion of the incubation, the cell suspension was poured into a 
sterile 50 ml conical tube and spun at 1000 X g for 20 minutes at 4
o
C.  The 
resulting supernatant was called the tertiary virus and was poured into a new 
sterile 50 ml conical tube and the pellet was discarded.  Five to ten 1ml aliquots 
were placed in cryogenic tubes and frozen at 
-
80
o
C, and the rest was kept as a 
working stock at 4
o
C in the dark.  Quaternary virus was generated the same way 
as tertiary virus.  However, the amplifications were not taken past the quaternary 
virus.  If more virus was needed, earlier virus aliquots were thawed and 
amplified. 
Protein Expression and Purification: 
hTEP1:  The purification of hTEP1 will be described in the results section. 
SF9:  An extract made from uninfected SF9 cells was purified exactly as 
the hTEP1 preparation to be used as negative control.  The fractions collected 
after the Q-column were the same fraction numbers as those collected for 
hTEP1 after purification on the Q-column. 
hTRF1:  His-hTRF1 (provided by Titia de Lange, Rockefeller University, 
NY) and His-XPress-hTRF1 (see virus info above) were produced by infecting a 
100 ml spinner culture of SF9 cells with the corresponding hTRF1 baculovirus at 
an MOI of 10.  The infection was allowed to proceed for 48 hours, at which time 
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the cells were collected by sedimentation at 1000 X g.  Cells were washed with 
cold 1X PBS three times and spun down at 1000 X g after each wash.  The cell 
pellet was weighed and 10X cell pellet volume of buffer R + 5 mM imidazole (50 
mM NaPi pH 7.4, 1M KCl, 0.2% Triton X-100, 7 mM BME, and 5 mM imidazole) 
was added.  The cells were Dounce homogenized using pestle A, and sonicated 
20 times at 4 pulses each.  0.1% PEI was added to this extract and stirred for 10 
minutes on a stir plate in the cold box.  The PEI precipitated extract was 
centrifuged at 11,000 X g  in a Beckman JA20 rotor for 30 minutes at 4
o
C.  In the 
meantime, the Ni-NTA matrix (Qiagen, Valencia, CA) was equilibrated to the 
buffer R + 5 mM imidazole.  After the centrifugation step, the crude extract was 
added to the Ni-NTA matrix and allowed to rotate for mixing over 30 minutes.  
The Ni-NTA and extract slurry was then poured into a column and the flow -
through collected separately as the column was washed with 10 column volumes 
of buffer R + 5 mM imidazole.  The bound protein was eluted using buffer R + 
350 mM imidazole.  Fractions were collected in 1 ml aliquots and each was 
tested for protein content using the Bradford dye reagent.  Fractions containing 
protein were then analyzed by SDS gel electrophoresis to determine in which 
fractions hTRF1 was present.  The fractions containing hTRF1 were then pooled 
and diluted in a buffer similar to buffer R but one that did not include any KCl or 
imidazole in order to bring the salt concentration down to 100 mM.  The diluted 
protein was then loaded onto a 1 ml heparin-sepharose column equilibrated to 
the 100 mM KCl buffer.  The protein was then eluted off of the column using a 
linear gradient taking the salt concentration from 100 mM to 1 M.  Fractions were 
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collected in 1 ml aliquots and analyzed for the presence of hTRF1, in the case of 
His-XPress-hTRF1 immunoblotting was performed using the XPress antibody 
(described later).  Fractions containing hTRF1 were dialyzed using the hTRF1 
dialysis buffer (20 mM HEPES pH 7.5, 1 mM BME, 500 mM KCl, and 20% 
glycerol). 
SDS polyacrylamide gels and Immunoblotting: 
 For all SDS gels, the Hoefer SE 260 Mini-Vertical Unit (GE Healthcare 
Life Sciences, Piscataway, NJ) was used.  Cast gels were 10 cm by 10.5 cm and 
1 mm thick. 
 hTEP1:  Protein samples were heated at 85
o
C for 10 minutes in the 
presence of SDS sample buffer (35 mM Tris-HCl pH 6.8, 5% glycerol, 1.7% 
SDS, 0.2% bromophenol blue, and 1 mM DTT).  The heated samples were 
quickly centrifuged on a table top centrifuge, and then loaded onto a SDS 
polyacrylamide gel (4% stacker and 6% separating).  The gel was run at 35 mA 
until the dye front had run off of the gel.  The gel was then silver stained for 
visualization. 
 For the immunoblotting of hTEP1, the samples were run on SDS gels.  
The proteins were then transferred onto a polyvinylidene fluoride (PVDF) 
membrane (Millipore, Billerica, MA) using the TE 22 Mini Tank Transfer Unit (GE 
Healthcare Life Sciences, Piscataway, NJ).  The transfer process was performed 
at 400 mA for three hours in CAPS buffer (10 mM 3-cyclohexylamino-1-propane 
sulfonic acid, 10% methanol, pH 10.5).  The PVDF was then removed from the 
transfer cassette and placed in a hybridization tube in the presence of blocking 
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buffer (2% nonfat dry milk in TBS-Tween [20 mM Tris-HCl pH 7.5, 170 mM NaCl, 
and 0.5% Tween 20]).  The PVDF membrane was blocked for 15 minutes at 
37
o
C while being rotated in a hybridization oven.  After the blocking step, the 
blocking buffer was discarded and the anti-Myc antibody 9E10 clone (Sigma-
Aldrich, St. Louis, MO) was diluted to a 1:5000 ratio in blocking buffer and added 
to the hybridization tube.  The primary antibody was allowed to incubate with the 
membrane for one hour at 37
o
C.  The antibody was then decanted and the 
membrane was washed with TBS-Tween containing 0.2% nonfat dry milk three 
times at 5 minute intervals.  After the washes, the secondary antibody of goat 
anti-mouse IgG conjugated HRP (Bio-Rad Laboratories, Hercules, CA) at a 
1:3000 dilution was added to the membrane in the hybridization tube and 
allowed to incubate as with the primary antibody.  The secondary antibody was 
also washed the same as the primary antibody.  Once the last wash was 
discarded, the membrane was housed in the hybridization tube to keep it from 
drying out.  In order to visualize the Western blot, a chemiluminescence reagent 
(25 mM luminol, 90 mM p-coumaric acid, 100 mM Tris-HCl pH 8.5, and 0.03% 
hydrogen peroxide in 10 ml water) was poured onto the membrane and allowed 
to sit for 1 minute before being decanted.  The membrane was then either 
exposed to film for autoradiography or visualized by a Fuji LAS-3000 instrument 
able to detect and digitally record the image from the chemiluminescence.   
 hTRF1:   All procedures were followed as with hTEP1 with the exception 
that an 8% separation gel was used.  The transfer procedure was carried out for 
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one hour.  The anti-XPress monoclonal antibody (Invitrogen, Carlsbad, CA) was 
used as the primary antibody at a 1:10,000 dilution. 
In Vitro Transcription: 
 In vitro transcription was used to generate radiolabeled hTR and control 
RNA molecules for hTEP1 activity assays (described later).  This reaction was 
optimized by creating the following mix:  0.1 unit pyrophosphatase (Sigma-
Aldrich, St. Louis, MO), 14 mM MgSO4, 1X T7 polymerase buffer (New England 
Biolabs, Ipswich, MA), 20 µM ATP, and 4 mM UTP, CTP and GTP, 10mM DTT, 
20 units RNase inhibitor (Roche, Nutley, NJ), T7 RNA polymerase (New England 
Biolabs, Ipswich, MA), 250ng template DNA, and 30 µCi [α -
32
P] ATP 
(PerkinElmer, Wellesley, MA).   Template DNA was generated by digesting 
pBS+-hTR with SacI and the empty pBS+ plasmid with AflIII to facilitate run off 
transcription of hTR and pBS+ (negative control) RNA’s.  The digested DNA was 
then gel-purified as described before. 
 The in vitro transcription mix was incubated at 37
o
C for 2 hours, and heat 
inactivated at 70
o
C for 15 minutes.  The reaction was placed on ice, 40 units of 
DNase I (Invitrogen, Carlsbad, CA) was added, and the reaction was incubated 
at 37
o
C for 15 minutes.  After this final incubation, the mixture was heat 
inactivated as before.  The mixture was then cleaned using the RNeasy Mini Kit 
(Qiagen, Valencia, CA).  A scintillation counter was used to measure total counts 
from each reaction. 
Electromobility Shift Assay (EMSA): 
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 Radiolabeled hTR and pBS+ RNA were prepared as described in the 
previous section.  Each 16 µl reaction included 1X telomerase buffer (50 mM 
Tris-HCl pH 8.2, 1 mM MgCl2, 2 mM EGTA, 1mM BME, 1 mM spermidine, and 
0.1 mM spermine), 10 units RNase inhibitor, and 40,000 CPM of radiolabelled 
RNA.  Because of the very low concentrations of hTEP1 protein, it was added up 
to volume limits.  Some reactions were run in the presence of cold inhibitor, 
which was either 30 µg of tRNA or 40 µg yeast RNA (Sigma-Aldrich, St Louis, 
MO).  Reactions were incubated on ice for 30 minutes and then 4 µl of 5X stop 
gel buffer (50% glycerol, 50 mM EDTA, and 0.5% bromophenol blue) was added 
to each tube.  The samples were then run on a 4% native acrylamide gel at 150 
volts. 
Fluorometry: 
 hTRF1 fluorescence was measured using a Cary Eclipse Fluorescence 
spectrophotometer (Varian, Palo Alto, CA) in 400 µl reaction volumes in the 
presence of 1X pol-α buffer (10 mM Tris-HCl pH 7.5, 5 mM MgCl2, and  7.5 mM 
DTT), and 100 nM hTRF1.  Protein and DNA concentration were selected based 
on titration studies.  Fluorescence emission scans and excitation scans were 
performed on hTRF1 to determine the optimum emission and excitation 
wavelengths.  The optimum excitation wavelength was determined to be 277 nm 
and an optimum emission wavelength of 335 nm at a slit width of 10 nm (Figure 
14).  For fluorescence quenching studies, first the solution with buffer and 500 
nM DNA was zeroed.  Then 100 nM protein was added while the cuvette was 
inside the instrument and quickly mixed by pipetting up and down.  A kinetic read 
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(0.2 seconds per read) was then initiated for 15 minutes.  Quenching with each 
DNA substrate (see below) was repeated at least 3-times and the quenching 
data was then averaged and plotted using the SigmaPlot software (Systat, Point 
Richmond, CA).   
 DNA substrates:  The DNA substrates used for the kinetic studies of 
hTRF1 are listed in Table 1.  Each strand was synthesized by Integrated DNA 
Technologies (Coralville, IA), and was then gel-purified using a 3 mm thick  
denaturing polyacrylamide gel.  UV shadowing was used to visualize the DNA 
band and to remove that piece of the gel.  The piece was then sheared using a 1 
ml syringe and eluted overnight in 3-4 ml elution buffer (300 mM NaOAc, 1 mM 
EDTA, and 0.1% SDS) at 4
o
C while rotating to mix.  The eluted DNA was then 
removed from the gel pieces by filtration though a syringe filter (2 µm pore size), 
then was ethanol precipitated by adding 3 equal volumes of 100% ethanol, 
placing in the freezer for a minimum of 30 minutes, and sedimenting at 11,000 X 
g in a Beckman JA20 rotor for 1 hour at 4
o
C.  Each DNA pellet was then 
resuspended using TE buffer and the concentration was measured using 
absorbance at 260 nm.  Double stranded DNA was generated by mixing equal 
concentrations of complementary strands with annealing buffer (50 mM Tris-HCl 
pH 7.5, 10 mM magnesium acetate, and 5 mM DTT), heating to 95
o
C for 5 
minutes, and cooling slowly to room temperature overnight. 
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Table 1.  DNA substrates used for hTRF1 fluorescence quenching.  Telomeric 
sequences are represented in bold lettering. 
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Name Sequence (5’-3’) Length  
PS38.1 ATCGCCTGAGTCAGAGCTAGCTAGCCCAGGATCCACCG 38  
PS38.2 CGGTGGATCCTGGGCTAGCTAGCTCTGACTCAGGCGAT 38 
KT5.1 ATCGCCTGAGTTAGGGTTAGGGTTAGGGGGATCCACCG 38 
KT5.2 CGGTGGATCCCCCTAACCCTAACCCTAACTCAGGCGAT 38 
KT5.3 ATCGCCTGAGTTAGGGTTAGGGTTAGGGTTAGGGGGATCCACCG 44 
KT5.4 CGGTGGATCCCCCTAACCCTAACCCTAACCCTAACTCAGGCGAT 44 
JT20.2 CCCTAACCCTAACCCTAACCCTAATGGCTTCAGCATCCTG 40 
JT20.3 CAGGATGCTGAAGCCATTAGGGTTAGGGTTAGGGTTAGGG 40 
JT20.4 CCCTAACCCTAATGGCTTCAGCATCCTG 28 
JT20.5 CAGGATGCTGAAGCCATTAGGGTTAGGGTTAGGG 34 
JT20.6 CCCTAACCCTAACCCTAATGGCTTCAGCATCCTG 34 
 41 
III. RESULTS 
hTEP1:   
The cDNA for Myc-tagged hTEP1 was generously provided by Lea 
Harrington (Ontario Cancer Institute-Amgen Institute, Toronto, Canada).  The 
Myc-hTEP1 cDNA was placed into the pBacPAK8 plasmid (Clontech, Mountain 
View, CA) for the creation of the hTEP1 baculovirus.  Due to the very large size 
of the insert (about 8 kbp), it was not possible to find two unique restriction 
enzymes for generating overhangs.  Therefore, hTEP1 was cut with a restriction 
enzyme that gave an overhang on one end and cut with a blunt cutting restriction 
enzyme at the other end, still allowing directionality in cloning.  hTEP1 was cut 
using NotI and SnaBI and pBacPAK8 was cut using NotI and StuI.  The 
fragments were gel-purified, ligated, and used to create the hTEP1 baculovirus 
(see Materials and Methods).  The blunt end ligation of the SnaBI site on Myc-
hTEP1 with the StuI site of the plasmid results in a loss of both restriction sites in 
the final product.  The resulting plasmid was used to generate the hTEP1 
primary baculovirus (see Materials and Methods). 
Upon analysis of the Western blot of the cells from the secondary virus 
preparation, the virus with the best protein expression was chosen and re-
amplified.  Using the amplified virus, a multiplicity of infection (MOI) (refers to the 
number of virus particles per cell) titration study was performed to determine the 
best virus titer for maximal protein production.  The experiments were performed 
in a 6-well plate, where in the first well no virus was added, then an MOI of 0.5, 
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1, 5, 10, and 20 were added respectively.  The infection was allowed to proceed 
for 48 hours and the cells were then lysed in SDS sample buffer for analysis via 
Western blots.  The MOI that resulted in the largest band of Myc-hTEP1 was 
used for further amplifications of hTEP1.  The MOI titrations of the Myc-hTEP1 
baculovirus demonstrated that an MOI of 5 or 10 is optimal for the hTEP1 
production.  In fact, once the MOI was increased up to 20, there was a noted 
decrease in protein expression (Figure 5a).  Although the MOI of 10 has a slight 
advantage to MOI of 5 in protein expression, due to the difficulties in amplifying 
the Myc-hTEP1 baculovirus, the MOI of 5 was used for subsequent large scale 
protein expressions. 
Upon determining the optimal MOI, a time course study was conducted to 
determine maximal protein expression over time.  The test was performed very 
similarly to the MOI study, except that infected wells were infected with the same 
MOI of virus.  Samples were taken at 24 hour intervals by removing the media 
from the cells and lysing the cells in SDS sample buffer.  Each sample was 
frozen at 
-
80
o
C until the final sample was taken, and then all samples were 
analyzed using immunoblotting.  The infection time that resulted in the brightest 
Myc-hTEP1 band in the Western blot was used for all infections for the 
amplification of hTEP1.  The time course studies demonstrated that the 48 hour 
incubation with the virus is optimal (Figure 5b).  In fact, a large drop in protein 
levels were observed once the virus was incubated for a longer period (Figure 
5b).  This loss of either the Myc-tag or degradation of hTEP1 became a major 
issue in the purification of hTEP1, which will be addressed later.     
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For the purification of hTEP1, three buffers were made: buffer A - no salt 
buffer (20 mM HEPES pH 7.8, 0.5 mM EDTA, 0.5 mM EGTA, 1 mM DTT, 0.1% 
NP40, and 10% glycerol); buffer B - 1M NaCl buffer (buffer A plus 1 M NaCl); 
and dialysis buffer (20 mM HEPES, 0.5 mM EDTA, 0.5 mM EGTA, 100mM KCl, 
1 mM BME, and 20% glycerol).  All purification steps were carried out by mixing 
buffer A and B in proportions to give the desired salt concentration.  At each step 
1 mg/ml of E64, Pepstatin, Leupeptin, and PMSF (all from Sigma-Aldrich, St. 
Louis, MO) were added to the buffers. 
200 ml of a SF9 cell suspension was infected with Myc-hTEP1 
baculovirus at an MOI of 5.  After 24 hours, 1 mg/ml of the cysteine-protease 
inhibitor E64 was added to the cells, as this significantly reduced the degradation 
of hTEP1 before the lysis step.  The cells were then incubated for another 24 
hours as determined by the time course study.  After 48 hours, the cells were 
spun down at 1000 X g for 10 minutes in a Beckman JA10 rotor.  The media was 
discarded and the cell pellet was resuspended in cold 1X PBS.  The washed cell 
pellet was weighed and extraction buffer (90% buffer A and 10% buffer B) was 
added up to seven times the weight of the pellet and was used to resuspend the 
pellet.  The cells were allowed to sit on ice for 10 minutes with extraction buffer.  
Then the cells were Dounce homogenized using pestle A for 20 times, sonicated 
10 times at 4 pulses each, and finally Dounce homogenized 5 times.  The extract 
was then poured into a 15 ml glass centrifuge tube and centrifuged at 11,000 X g 
in a Beckman JA20 rotor for 45 minutes or until the turbidity of the extract was 
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low (at 4
o
C).  The crude extract obtained was decanted and the volume 
measured. 
One problem that we encountered during the extraction process was the 
inability to obtain all of the Myc-hTEP1 from the cells in the first extraction 
(Figure 6a).  Therefore, in order to increase the hTEP1 yield, the cell pellet from 
the previous step was resuspended in half the volume of extraction buffer as 
previously used.  The extraction process was repeated and the new extract was 
cleared.     
Another problem that we encountered was the loss of the ability to detect 
Myc-hTEP1 using immunoblotting after Myc-hTEP1 had been extracted (Figure 
6b).  Detection by immunoblotting became imperative because full length hTEP1 
was produced in very low levels and was therefore difficult to detect using SDS 
gels alone.  The detectable amounts of Myc-hTEP1 would decrease on an hourly 
basis, with significant decreases in a 24 hour period even if sample was stored at 
-
80
o
C (Figure 6b).  The loss of hTEP1 was partly solved by adding E64 to the 
cells prior to extraction (data not shown).  Cysteine-proteases are expressed 
upon infection of SF9 cells and thus by adding the inhibitor 24 hours prior to 
extraction, much of the intracellular degradation of the over-expressed protein 
can be reduced (Hom and Volkman, 1998; Marensen and Justesen, 2001).  The 
second step to reduce degradation was the ammonium sulfate precipitation of 
the crude extracts.  hTEP1 was precipitated out of solution by the addition of 
25% ammonium sulfate (Figure 7).  The precipitation was carried out by adding 
solid ammonium sulfate (Sigma-Aldrich, St. Louis, MO) slowly (over 30 minutes) 
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up to 25% of total volume while stirring on ice.  The mixture was then allowed to 
stir on ice for another 30 minutes to allow for all of the ammonium sulfate to go 
into solution.  Then the precipitated protein was sedimented at 11,000 X g in a 
Beckman JA20 rotor for 30 minutes.  The supernatant was discarded, and the 
pellet was resuspended in the same volume of extraction buffer as the cells were 
first resuspended in.  This suspension was also sonicated one time for 10 pulses 
to break apart any leftover pelleted protein, and was then centrifuged at 1000 X g 
for 10 minutes to remove any insoluble protein.  Finally the resolublized protein 
was dialyzed overnight in 100 mM salt buffer at 4
o
C.  The Myc-hTEP1 
resuspended from the 25% ammonium sulfate cut remained stable in solution for 
up to one month (data not shown).   
The more stable Myc-hTEP1 was then run on a 10 ml quaternary amine 
column (Q-column) equilibrated to 100 mM salt buffer, using a Biologic DuoFlow 
FPLC system (Bio-Rad Laboratories, Hercules, CA).  The flow-through was 
collected separately, followed by five column volumes of wash.  Then the protein 
was eluted using a linear gradient from 100 mM NaCl to 1 M NaCl collected in 1 
ml fractions.  20 µl of each fraction was mixed with 140 µl of water and 40 µl of 
Bradford dye reagent (Bio-Rad Laboratories, Hercules, CA) each in a well of a 
96-well clear plate.  The presence of protein was qualitatively measured by 
reading the plate at 595 nm.  The absorbance was plotted to visualize the 
relative fractions where protein is present.  The fractions that included the 
proteins from the third peak of elution, which contained hTEP1, were collected 
and dialyzed overnight against the dialysis buffer (described above) (Figure 8a).  
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The final protein was run on a 6% SDS polyacrylamide gel for visualization of the 
protein through silver staining and Western blotting (Figure 8 b and c).  Due to 
the very low expression of hTEP1, it was not possible to purify the protein further 
as it would become too dilute for detection.  However, this is the first time full 
length hTEP1 has been purified to this level. 
To determine the activity of the Myc-hTEP1, electromobility shift assays 
(EMSA) were employed.  Radiolabeled hTR (substrate) and pBS+ RNA 
(negative control) were prepared for this assay.  To obtain hTR for this purpose 
we obtained the hTR cDNA from 293-S cells (see Materials and Methods).  Upon 
generating the cDNA library, it was amplified using PCR.  For the PCR 
experiments, the primers KT3.1 (5’ TATAAGCCGACTCGCCCG 3’) and KT3.2 
(5’ GCATGTGTGAGCCGAGTC 3’) were used (Figure 9a).  These optimal 
primers were designed using the Vector NTI software (Invitrogen, Carlsbad, CA).  
The PCR reactions were carried using the FailSafeTM PCR System (Epicentre 
Biotechnologies, Madison, WI).  The FailSafeTM PCR System is a PCR 
optimization kit, which comes with a mix of thermostable polymerases which 
includes both high fidelity and low fidelity polymerases.  The kit also comes with 
a set of twelve different PCR buffers (labeled A-L), each including dNTP’s and 
different amounts of magnesium chloride for optimization of the reaction.  For the 
hTR PCR, 1 µM of each primer, 1 µl of cDNA, 1 unit of the enzyme mix were 
added to enough water to make twelve 12.5 µl solutions, and 12.5 µl of each 
PCR buffer was added to its corresponding tube to make a 25 µl final solution.  
Each tube was gently mixed and placed into the thermocycler.  The cycling 
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program involved an initial 98
o
C denaturation step for 2 minutes, followed by 30 
cycles of 98
o
C for 30 seconds, 55
o
C for 30 seconds, and 72
o
C for 45 seconds.  
The tubes were then placed in 4
o
C until further analysis.  The analysis involved 
running 2 µl of each reaction on a 1% agarose gel.  Reactions that had a band 
around the 500 bp mark were chosen for further analysis (Figure 9b).   PCR 
products were digested with XbaI and PvuII restriction enzymes.  PCR products 
that responded as expected to these digests were chosen for further cloning.   
The hTR cDNA was placed downstream of the T7 promoter in the pBS+ 
plasmid to generate pBS+-hTR (see materials and methods) for the production 
of hTR, and pBS+ alone was used to generate the negative control RNA.  In vitro 
run off transcription was used to generate hTR and pBS+ control RNA (materials 
and methods). 
For most of the EMSA experiments, the ammonium sulfate cut of hTEP1 
was used due to the higher concentration of the protein.  In these EMSA 
experiments hTEP1 had a clear specificity for hTR and not for the pBS+ RNA 
(Figure 10).  The binding of hTEP1 with hTR was quite strong, even in the 
presence of yeast total RNA (Figure 11, lane 4).  However, this interaction could 
be disturbed by using whole cell RNA from a human cancer cell line (Figure 11, 
lane 5), which could be attributed to endogenous hTR molecules.  Furthermore, 
the hTEP1/hTR band on the gel could not be super-shifted using the anti-Myc 
antibody (Figure 11, lane 3), though this is not surprising since the hTEP1-hTR 
complex is so large that the addition of an antibody will not make a difference in 
the total size and cause a supershift.  
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 Since hTEP1 could not be purified fully, it was important to test whether 
the hTR binding observed was not due to a SF9 protein contaminant.  Therefore, 
uninfected SF9 cells were harvested, and protein was purified as with hTEP1.  
The same fractions as those obtained in the hTEP1 preparation were collected 
and used in EMSA experiments (Figure 12, lanes 2-5).  We did not observe any 
hTR specific binding, since most RNA binding activity could be competed in 
presence of competitor RNA (Figure 12, lanes 2-5).  However, even though the 
hTEP1 concentrations were very low after the collection of the Q-column 
fractions (80 µg/ml total protein), we could still observe binding to hTR (Figure 
12, lanes 14 and 17).  This binding was also observed when the ammonium 
sulfate cut, was run on a SEC250 size exclusion column (Figure 12, lanes 18 
and 19), though this hTEP1 prep is not as pure as the Q-column fractions.  
When using the higher concentration ammonium sulfate cuts, we did not observe 
any super-shift with the Myc antibody (Figure 11, lane 3).  However, with the 
more pure fractions of hTEP1, even though we did not see a super-shift when 
the antibody was added, we saw more clear binding of hTR in the presence of 
the Myc antibody and more of the protein was pulled out of the well (Figure 12, 
lane 17).   
 In summary, I have successfully expressed and purified full length hTEP1 
using the baculovirus expression system.  The key to this purification was to 
quickly separate hTEP1 from other proteins that were degrading it.  hTEP1 
expressed in this manner has great affinity for hTR which was cloned and 
produced in quantities necessary to carry out these experiments.   
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hTRF1:   
The hTRF1 cDNA was successfully cloned out of a total human cDNA 
library using polymerase chain reaction (see Materials and Methods).  The cDNA 
was then placed downstream of the His-tag and the XPress-tag of the pRSET 
plasmid, and the newly tagged sequence was then placed into BacPak 8 for the 
creation of the baculovirus (see Materials and Methods).  Plaques were analyzed 
using immunoblotting with the anti-XPress antibody, and one plaque was chosen 
for the amplification of hTRF1 (see Materials and Methods).  hTRF1 was 
expressed and purified successfully using the methods previously described 
(Figure 13). Off of the final heparin column, two peaks of protein were obtained.  
Both peaks contained a band at 66 kDa which may have corresponded with 
hTRF1 (Figure 13a).  However, the immunoblot with the anti-XPress antibody 
indicated that the His-tagged hTRF1 was only present in the first protein peak 
(Figure 13b, lane 1).  Furthermore, this was also the cleanest peak with only one 
other major protein band visible after silver staining the gel (Figure 13).  
Fluorescence studies:  Intrinsic fluorescence was chosen as the main 
detection tool for hTRF1 interaction with telomeric DNA.  Intrinsic fluorescence is 
an attractive tool, because it is a very direct and simple way to measure pre-
steady state kinetics of protein activity.  To determine if intrinsic protein 
fluorescence could be used, excitation and emission spectra were taken over the 
ranges expected for tryptophan fluorescence.  The excitation wavelength of 
hTRF1 was found to be 283 nm and emission at 335 nm, typical of tryptophan 
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excitation and emission (Figure 14).  This fluorescence was also quenched upon 
binding of telomeric DNA (Figure 15 and Table 1) and was not quenched upon 
incubation with non-telomeric DNA (Figure 15 and Table 1) in equilibrium 
readings (Figure 16).  This interaction was also quite stable even as salt was 
titrated into the mix, as there was no observable change in fluorescence 
quenching even at 300 mM extra salt (Figure 16).   
Upon establishing that hTRF1’s fluorescence can be quenched in the 
presence of telomeric DNA, the next step was to make pre-steady state 
measurements of hTRF1 binding to telomeric DNA.  Several different DNA 
substrates were chosen to complete this task (Table 1 and Figure 15).  
Substrates with 3-4 telomeric repeats were chosen based on early equilibrium 
DNA binding studies, which showed that three repeats are the minimum required 
to detect binding in an EMSA assay (Zhong et al. 1992).  The first attempts at 
measuring the pre-steady state binding of hTRF1 to telomeric DNA was 
performed on a stopped flow instrument, which allows for measurement of 
intrinsic fluorescence quenching down to millisecond time points.  Quenching of 
hTRF1 fluorescence could not be detected in the millisecond time range (data 
not shown).  Upon increasing the measurement time to 10 seconds, the first 
fluorescence quenching of hTRF1 due to binding of DNA could be measured 
(Figure 17).  However, this quenching was observed regardless of the DNA 
substrate used.  Yet EMSA experiments carried out in our lab and published by 
others indicated that hTRF1 binds telomeric DNA specifically.  Furthermore the 
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equilibrium binding experiment shown in Figure 16 also confirmed that hTRF1 
exhibits a higher affinity for telomeric DNA versus non-telomeric DNA.  
 Based on the observations highlighted above, hTRF1 fluorescence 
quenching was carried out in a fluorometer (see materials and methods), where 
the measurements could be carried out in minute time frames.  Using the 
fluorometer, it was determined that the fluorescence quenching was surprisingly 
slow, taking fifteen minutes (Figures 18-23).  As observed with the stopped flow 
measurements, there is a drop in fluorescence for the first two minutes 
regardless of substrate used (Figures 18-23).  However, after two minutes, there 
is a distinct difference between DNA with and without telomeric tracts (Figure 18 
compared to 19-23).  The non-telomeric DNA exhibits a quenching for the first 
two minutes (Figure 18), but then there is no further fluorescence quenching.  
The telomeric substrates all exhibit further quenching after this first two minute 
window (Figures 19-23).  Furthermore, the quenching data for hTRF1 binding to 
non-telomeric DNA fits only a single exponential decay curve (Figure 18), 
indicating a single event taking place (i.e. protein binding to DNA).  The 
quenching data for all of the telomeric substrates except for one (KT5.3+KT5.4, 
Figure 20) fit a double exponential decay curve (Figures 19,21-23), indicating 
that two events are taking place.  One of these events is the binding of the DNA 
molecule as observed with non-telomeric DNA.  It is theorized that the second 
event may very likely be a conformational change that allows hTRF1 to more 
fully bind telomeric DNA, and this process is quite slow.  However further studies 
are required to fully understand what is taking place and what the true rates are.  
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One curious aspect of this study is that the substrate with four internal telomeric 
repeats (KT5.3+KT5.4) had fluorescent quenching that fit a single exponential 
decay curve (Figure 20).  Nevertheless, the quenching observed is still stronger 
than that with the non-telomeric substrate. 
 Even though there is a very apparent difference between non-telomeric 
DNA and telomeric DNA, there is not a very large difference between the binding 
of hTRF1 to the different telomeric substrates (Figure 24).   hTRF1 does not 
discriminate between an internal telomeric repeat or an end repeat (Figure 19 a 
and b).  hTRF1 also does not interact differently with blunt telomeric ends or one 
with an overhang (Figure 24a).  The only major difference observed is between 
three internal repeats (KT5.1+KT5.2) and four internal repeats (KT5.3+KT5.4).  
This difference is due to, as mentioned earlier, KT5.3+KT5.4 being the only 
substrate that led to a decay that fit a single exponential curve.  Part of the 
reason why not all of the curves fit perfectly is a spike in fluorescence right 
around the eight minute mark (Figure 20, 21 and 23).  This spike cannot be a 
simple coincidence, since data was collected for each substrate at least three 
separate times if not more.  Further evidence for this spike not being a random 
phenomenon is that in all three cases it is occurring around the same time frame.  
Since the exact cause of this spike is unknown further studies are needed to 
determine the reason for its occurrence.   
 In summary, here I have shown the first experiments elucidating how 
hTRF1 binds to DNA.  The data clearly suggest that hTRF1 binds both telomeric 
and non-telomeric DNA, though binding to non-telomeric DNA is quite weak.  
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Although very slow, hTRF1 recognizes telomeric DNA and potentially goes 
through a conformational change that allows it to bind this DNA much more 
strongly.  Further tests are needed to measure the exact dissociation constants 
for hTRF1 binding to telomeric and non-telomeric DNA substrates. 
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Figure 5.  Immunoblots of Myc-hTEP1 expression optimization.  a. MOI titration 
study where, lane 1 is the uninfected control.  Lanes 2-6 represent MOI of 0.5, 1, 
5, 10 and 20 respectively.  b. Time course of infection study with the Myc-hTEP1 
baculovirus.  Lane 1 is the non-infected control.  Lanes 2-6 are samples taken at 
24, 48, 72, 96 and 120 hours respectively.
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Figure 6.  Immunoblots revealing Myc-hTEP1 degradation.  a. Lane 1, cells were 
directly lysed in SDS sample buffer (materials and methods) and loaded onto the 
gel.   Lane 2, first crude extract from cells.  Lanes 3-4, re-extraction from the 
pellet formed after centrifugation of each extract.  b. The immunoblot in each 
lane was performed on the same sample over 3 different days.  Sample was 
saved at -80
o
C over this time.  After 48 hours the myc tag is completely lost. 
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Figure 7.  Immunoblot of Myc-hTEP1 after an ammonium sulfate precipitation.  
Lanes 2, 7 and 8 were left empty.  Crude extract is present in lane 1.  Lanes 3-6 
are the supernatants from a 10%, 25%, 40%, and 60% ammonium sulfate 
precipitation respectively.  Lanes 9-12 contain the pellets from the same 
precipitations shown in lanes 3-6.  hTEP1 is present in the 25% pellet (lane 10).
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Figure 8.  Purification of Myc-hTEP1.  a. Chromatogram of Q-Sepharose 
fractionation of hTEP1.  The graph represents protein as determined by a 
Bradford assay versus fraction number.  Peak 1 is the flow through and bound 
proteins were eluted with a linear salt gradient.  Peak 2 represents the first 
elution and does not contain hTEP1, and peak 3 represents hTEP1.  b. Silver 
stained SDS gel of the protein obtained from the purification over the Q-column, 
Myc-hTEP1 is running at the 250kDa molecular weight standard.  c. Western blot 
of the purified Myc-hTEP1. 
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Figure 9.   a. Cartoon of hTR cloning.  Sense and antisense primers indicate the 
location of hTR on each plasmid.  hTR was placed downstream of the T7 
promoter and not the T3 promoter in the pBS+ plasmid.  b. An agarose gel of the 
hTR cDNA PCR products.  The product in the lane on the right was performed 
with the optimum amplification buffer described in Materials and Methods.    
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Figure 10.  EMSA determining the activity and specificity of hTEP1 in presence 
of hTR and non-specific pBS+ RNA.   Lanes 1-10 are in the presence of hTR 
and lanes 11-20 are in the presence of pBS+ RNA.  Protein was titrated in lanes 
2-5 and 12-15.  tRNA was titrated in lanes 6-10 and 16-20.  In the presence of 
the competitor the binding of hTEP1 to hTR is significantly enhanced (lanes 6-
10) as non-specific binding by contaminating proteins is reduced.  The reduction 
in binding of the pBS+ RNA in presence of cold competitor (lanes 16-20) reveals 
that full-length hTEP1 binds RNA molecules with specificity. 
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Figure 11.  EMSA experiment determining the effect of different competitors and 
antibody on the binding of hTEP1 with hTR.  Only total human cancer cell 
(H1299) RNA is capable of disrupting the hTEP1/hTR interaction. 
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Figure 12.  EMSA experiments comparing the mono-Q fractions of SF9 proteins 
(lanes 2-5), mono-Q purified hTEP1 (lanes 14 and 17) with Sec250 purified 
hTEP1 (lanes 18-19).  All lanes have 800ng of protein, which was determined by 
the maximum volume of the Q-peak 2-hTEP1 that could be used.  All lanes also 
contain 30 µg of tRNA unless stated otherwise.  Q-peak 1 is the first peak of 
proteins that come off of the Q-column which does not contain any detectable 
hTEP1.  Lanes 16 and 17 contain 1 µg of anti-Myc antibody (9E10), which can 
stabilize the hTEP1 binding to hTR (lane 17).
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Figure 13. His-Xpress-hTRF1 purification gel and Western blot.  1µg of protein is 
loaded into each well.  a. Silver stained SDS gel of the two heparin protein pools.  
b. Immunoblot of the same samples represented in the silver stained gel.  The 
immunoblot clearly demonstrates that hTRF1 is only present in the first protein 
peak that comes off of the heparin column (lane 1). 
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Figure 14.  Excitation and emission spectra of hTRF1.  a. Excitation spectrum of 
hTRF1 measuring emission at 340 nm.  b. Emission spectrum of hTRF1 with 
excitation at 275 nm.
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Figure 15.  Cartoon of hTRF1 substrates.  Black lines represent random 
sequences used to anneal the substrates correctly 
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Figure 16.  Equilibrium fluorescence quenching of hTRF1 by telomeric DNA and 
salt titration.  Intrinsic fluorescence of hTRF1 is quenched only in the presence of 
telomeric DNA even in addition of excess salt (squares).  The quenching effect of 
non-telomeric DNA (triangles) is not statistically different than that of buffer alone 
(circles).
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Figure 17.  Stopped flow intrinsic fluorescence measurements using hTRF1 in 
10 second readings.  a. hTRF1 fluorescence in the absence of DNA.  b. hTRF1 
fluorescence quenching upon the addition of DNA, regardless of sequence.
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Figure 18.  Graph depicting the quenching of hTRF1’s intrinsic fluorescence with 
non telomeric DNA (PS38+PS38.2).  Top graph is a direct measurement of 
fluorescence quenching.  The red line represents a single exponential decay 
curve.  The bottom panel represents the fit of the curve to the fluorescence data 
by looking at the residual values around the curve. 
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Figure 19.  hTRF1 intrinsic fluorescence quenching by the substrate 
KT5.1+KT5.2 (3 internal repeats).  The red line represents a single exponential 
decay curve and the green line represents a double exponential fit.  The second 
panel represents the residuals from the single exponential curve (red line in top 
panel).  The third panel depicts the residuals produced from the double 
exponential plot (green line in top panel).
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Figure 20.  Intrinsic fluorescence quenching for the KT5.3+KT5.4 (four internal 
repeats).  In the top panel the red line for a single exponential decay is 
overlapped by the green line of a second exponential decay curve.  Therefore, 
this data only fits a single exponential decay and since the residual values are 
also identical only one is shown here in the bottom panel.
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Figure 21.  Intrinsic fluorescence quenching for the JT20.2+JT20.3 substrate 
(four end repeats) and residual values as described for Figure 19. 
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Figure 22.  Intrinsic fluorescence quenching for the JT20.4+JT20.3 substrate (2 
double stranded end repeats with a double stranded overhang) and residuals as 
described in Figure 19.  
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Figure 23.  Intrinsic fluorescence quenching for the JT20.5+JT20.6 substrate 
(three end repeats) and residuals as described in Figure 19. 
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Figure 24.  Comparison of hTRF1 quenching between different substrates.  In all 
graphs PS38+PS38.2 is present for reference.  a. Comparison of all substrates 
with the telomeric repeats at the ends.  b. Comparison of substrates with internal 
telomeric repeats.  c. Comparison of substrates with three repeats. d. 
Comparison of substrates with four repeats.
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IV. DISCUSSION AND CONCLUSIONS 
hTEP1:  
  Here we report the first ever purification of full length hTEP1 (Figure 8).  
The fact that full length hTEP1 is so unstable in whole exptracts may account for 
why only small sub-domains were partially purified previously (Poderycki et al., 
2005).  A significant advance was the addition of a precipitation step early in the 
purification, which was the 25% ammonium sulfate precipitation (Figure 7).  At 
25% ammonium sulfate, most other proteins do not precipitate, not only 
significantly purifying hTEP1 but more importantly separating it from the 
protein(s) that quickly degrade it.  The next big hurdle that must be tackled is 
boosting the production of hTEP1, allowing the production of even more pure 
protein for future in-depth biochemical studies.  We have partially overcome this 
limitation with a baculovirus expression system, however, there is still room for 
further progress in this area. 
 In this thesis, I have also demonstrated that full length hTEP1 binds hTR 
specifically (Figures 10 and 12).  This interaction could not be competed with 
tRNA or whole yeast RNA.  The interaction of hTEP1 with in vitro transcribed 
hTR can only be competed with the whole cell RNA of immortalized human cell 
line H1299 (Figure 11), which is most likely due to the presence of endogenous 
hTR.  We also generated a random RNA molecule the same length as hTR.  
hTEP1 has some slight interaction with this molecule, but this interaction is easily 
competed away in the presence of competitor RNA (Figure 10).  This specificity 
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for hTR in vitro would indicate that other segments of hTEP1 other than the p80 
homology domain play a role in hTR binding.  Another possible explanation could 
be that the hTEP1 in this work was produced in a eukaryotic system while the 
p80 homology domain was produced in E. coli (Poderycki et al., 2005).  
Therefore, we can not rule out post translational modifications as a reason why 
our protein binds hTR better in vitro. 
 Very recently Cohen et al., (2007) published the purification of catalytically 
active telomerase.  In this study they used partial protein digests and mass 
spectroscopy to identify some of the protein components of telomerase and 
found that their protein only contained TERT and dyskerin.  Though they did not 
find TEP1 as part of this complex, it can not be ruled out that hTEP1 still plays a 
critical role in telomere maintenance in vivo.  For example, even though the E. 
coli polymerase III requires beta clamp for its function, during the purification the 
beta clamp may be lost depending on different salt conditions (Cull and 
McHenry, 1995).  Therefore, though hTEP1 did not co-purify with the enzymatic 
activity of telomerase, there is no evidence that it does not play an important role 
in telomerase activity and telomere length maintenance.  In fact, the evidence in 
this work that shows hTEP1 interacts with hTR specifically gives new importance 
to find what the exact role of hTEP1 is in telomere maintenance.  Cohen et al., 
simply followed the activity of telomerase in G-strand synthesis.  hTEP1 may 
play a role in C-strand synthesis, which our lab believes is carried out in concert 
with G-strand synthesis in vivo.  The purification of this difficult protein puts us 
closer to reconstituting telomeric replication in vitro. 
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 In conclusion, we have generated stable full length-hTEP1 which can bind 
its target (hTR) with specificity in vitro.  Purifying full length hTEP1 will greatly 
enhance our ability to study the function of this protein and its greater role in 
telomeric maintenance.  Since hTEP1 may be the bridge between hTERT and 
other possible proteins that create the telomerase complex, by being able to 
generate full length-functional hTEP1, we are one step closer to reconstituting 
the full (G and C strand synthesis) telomerase reaction in vitro. 
hTRF1:   
 Here I have reported the first pre-steady state measurements of hTRF1 
binding to DNA.  The biggest surprise from these results was the discovery that 
hTRF1 binds non-telomeric DNA (Figures 17 and 18).  The current dogma is that 
hTRF1 is a protein that only binds telomeric DNA.  However, this picture is much 
more complicated.  hTRF1 binds all DNA, however it has a higher affinity for 
telomeric DNA.  This concept makes great sense since the Myb-like binding 
domain of hTRF1 is a DNA binding domain (reviewed in Lipsick 1996).   
 The second aspect of these experiments that was quite interesting was 
the fact that in the presence of telomeric DNA, the hTRF1’s intrinsic fluorescence 
was quenched in a way that fit a double exponential decay (Figures 19, 21-23).  
This indicates that there are two separate events taking place.  We predict that 
the first event is the DNA binding event.  The second event is most likely due to 
a conformational change responsible for binding telomeric DNA specifically.  This 
conclusion is drawn from our work and is supported by an additional line of 
research.  Nashikawa et al. (2001) solved an NMR structure of the hTRF1 DNA 
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binding domain.  In this study they discovered that an N-terminal arm of the 
binding domain becomes more ordered and interacts with the minor groove of 
the telomeric DNA.  Our studies fit well with the information gathered from the 
NMR data. 
 One aspect of the fluorescence quenching that was puzzling was the 
presence of a spike in fluorescence around eight minutes that only occurred with 
half of the substrates (Figures 20, 21, and 23).  This made curve fitting for the 
data of those substrates difficult.  The exact reason for this spike is unknown.  
One could argue that this spike was a result of more than one protein interacting 
with the DNA, especially in cases where there were four telomeric repeats, 
however, in one case the spike occurred in the presence of three repeats.  
However, in studies where only the DNA binding domain of hTRF1 was used, 
only two telomeric repeats were required (Nashikawa et al., 2001; König et al., 
1998), and three repeats were the minimum needed when using full length 
hTRF1 (Zhong et al., 1992; Bianchi et al., 1997).  Further experiments are 
necessary with a wider range of substrates to determine the exact nature and the 
relevance of this spike. 
 Through this study we have made a significant progress in understanding 
how hTRF1 works.  Our model indicates that hTRF1 binds DNA, and scans it for 
telomeric tracts.  Upon reaching the telomeric tract, hTRF1 slowly changes 
confirmation and binds the telomeric DNA more stably (Figure 25).  This model 
fits very well with the role hTRF1 plays in the cell as a protein that binds and 
stabilizes telomeric DNA.
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Figure 25.  Cartoon of the possible hTRF1 mechanism.  a. The blue ribbon 
represent random DNA sequences.  The hTRF1 homodimer is able to bind this 
DNA but only weakly and can easily fall off.  b. The red ribbon represents a 
stretch of telomeric DNA.  The hTRF1 homodimer goes through a conformational 
change upon interacting with the telomeric DNA, allowing it to bind tightly.
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